Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: Everolimus, Exemestane, Tamoxifen, Fulvestrant, Anastrozole, Letrozole, Toremifine; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 8
States / cities: Fort Myers, Florida • Hollywood, Florida • Pensacola, Florida + 5 more

Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
Interventions: RYZ101; Drug
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 25
States / cities: Phoenix, Arizona • Irvine, California • San Diego, California + 21 more

Conditions: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer, Fulvestrant, Palazestrant
Interventions: OP-3136, Fulvestrant, Palazestrant; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Sarasota, Florida • New Orleans, Louisiana • Boston, Massachusetts + 4 more

Conditions: Advanced or Metastatic Breast Cancer
Interventions: AND019 PO QD; Drug
Lead sponsor: Kind Pharmaceuticals LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: everolimus, anastrozole, letrozole, tamoxifen citrate, fulvestrant, megestrol acetate; Drug
Lead sponsor: Emory University; Other
Eligibility: 19 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
Interventions: NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole; Drug
Lead sponsor: NiKang Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: La Jolla, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: Advanced Solid Tumors, Metastatic Triple Negative Breast Cancer
Interventions: NK012 and carboplatin; Drug
Lead sponsor: Nippon Kayaku Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: ER-Positive HER2-Negative Breast Cancer
Interventions: AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib, Luteinizing hormone-releasing hormone (LHRH) agonist; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 30
States / cities: Mobile, Alabama • Springdale, Arkansas • Harbor City, California + 25 more

Conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Recurrent Breast Carcinoma, TP53 wt Allele, Unresectable Malignant Solid Neoplasm
Interventions: MDM2/MDMX Inhibitor ALRN-6924, Paclitaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: PF-07248144, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 102
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more

Conditions: ER+ HER2- Advanced Breast Cancer
Interventions: AZD9496; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: Sarasota, Florida • New York, New York • Nashville, Tennessee

Conditions: Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma, MEK1 Gene Mutation, MEK2 Gene Mutation, Metastatic Breast Cancer
Interventions: Mirdametinib, Fulvestrant; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more

Conditions: Breast Neoplasms
Interventions: Iza-bren, Nab-paclitaxel, Paclitaxel, Capecitabine, Carboplatin, Gemcitabine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 46
States / cities: Hot Springs, Arkansas • Cerritos, California • Long Beach, California + 35 more

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions: Akt Inhibitor GSK2141795, Laboratory Biomarker Analysis, Trametinib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Buffalo, New York + 4 more

Conditions: Advanced Breast Cancer
Interventions: ARV-471, Fulvestrant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 87
States / cities: Encinitas, California • Fountain Valley, California • Fresno, California + 69 more

Conditions: Breast Cancer
Interventions: [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib, Fulvestrant, Goserelin; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 6
States / cities: Los Angeles, California • Newport Beach, California • Westwood, Kansas + 3 more

Conditions: Breast Cancer
Interventions: Sapanisertib, Fulvestrant, Exemestane; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 30
States / cities: Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more

Conditions: Breast Cancer
Interventions: Gedatolisib, Palbociclib, Letrozole, Fulvestrant; Drug
Lead sponsor: Celcuity Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Corona, California • Fountain Valley, California + 17 more

Conditions: Breast Neoplasms
Interventions: Fulvestrant, Sapanisertib; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 30
States / cities: Mobile, Alabama • Bakersfield, California • Fullerton, California + 26 more

Conditions: Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer
Interventions: Palazestrant, Ribociclib, Alpelisib, Everolimus, Atirmociclib; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 14
States / cities: Gilbert, Arizona • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive Tumor, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Triple-negative Breast Carcinoma
Interventions: Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Decitabine, Pembrolizumab; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 4
States / cities: Edgewood, Kentucky • Columbus, Ohio • Charlottesville, Virginia + 1 more

Conditions: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Interventions: Giredestrant, Giredestrant-matched Placebo, Letrozole, Letrozole-matched Placebo, Palbociclib, LHRH Agonist; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 37
States / cities: Fountain Valley, California • Long Beach, California • San Leandro, California + 32 more

Conditions: Breast Cancer
Interventions: Ribociclib, Everolimus, Exemestane; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 25
States / cities: Chandler, Arizona • Fayetteville, Arkansas • Los Angeles, California + 20 more

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 9
States / cities: Duarte, California • Grand Rapids, Michigan • Conroe, Texas + 5 more

Search by objective public record fields.

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

Phase II Study of Everolimus Beyond Progression

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

AZD9496 First Time in Patients Ascending Dose Study

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors